Study of financial burden in patients diagnosed with colorectal cancer

Study ID: EAQ162CD

Longitudinal assessment of financial burden in patients with colon or rectal cancer treated with curative intent

This research trial studies the financial burden in patients with stage I, II or III colon or rectal cancer who will undergo treatment. Collecting data from patients about their cost and quality of life may help doctors to better understand the impact of cancer treatment on a patient’s employment and finances.

Participants in this trial complete questionnaires that include queries on health care costs, impact of those costs, access and utilization of financial resources, employment, quality of life, self-efficacy and socio-demographics at the time of trial registration. Patients then answer these questions three, six, 12 and 24 months following registration.

Patients must have newly diagnosed colon or rectal cancer (initial diagnosis, either a biopsy or curative surgery, whichever is most recent) with life expectancy of > 24 months and within 60 days of registration and have not yet received radiation or chemotherapy.

Cancer must be at stage I, II, or III at time of enrollment, and patient will be treated with curative-intent.

Patients are ineligible if they are already enrolled on a treatment clinical trial at the time of registration. They can remain on the study if they subsequently enroll on a treatment clinical trial during the study time period. Patients who choose not to receive radiation and/or chemotherapy after a curative-intent surgery are eligible.

History of previous malignancy (except non-melanoma skin or cervical in-situ cancer) treated (with either surgery, chemotherapy, and/or radiation) within the past three years are not eligible.

Inclusion Snapshot

  • Must have been newly diagnosed with colon or rectal cancer
  • Must not yet have received radiation or chemotherapy

Contact Information

Lankenau Institute for Medical Research trial